The Journal of Pediatrics of Korean Medicine (대한한방소아과학회지)

The Association of Korean Oriental Pediatrics (대한한방소아과학회)
권호 표지
DOI QR코드

DOI QR Code

The Efficacy of Ephedra sinica, Panax ginseng, and Alisma orientale Extract on Insulin resistance induced by Non-alcoholic fatty liver disease (NAFLD)

마황, 인삼, 택사 복합추출물의 endocannabinoid system 억제를 통한 비알콜성 지방간 유도 인슐린저항성 개선 효과

  • Kim, Ki Bong (Dept. of Pediatrics, School of Korean Medicine, Pusan National University) ;
  • Ahn, Sang Hyun (Dept. of anatomy, college of Korean Medicine, Semyung University)
  • 김기봉 (부산대학교 한의학전문대학원 소아과학교실) ;
  • 안상현 (세명대학교 한의과대학 해부학교실)
  • Received : 2020.09.15
  • Accepted : 2020.11.22
  • Published : 2020.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives This study aimed to investigate the efficacy of Ephedra sinica (E. sinica), Panax ginseng (P. ginseng), and Alisma orientale (A. orientale) Extract (MIT) on insulin resistance induced by Non-alcoholic fatty liver disease (NAFLD). Methods C57BL /6 male mice (8-week-old, 20 g) were divided into four groups: control group (Ctrl), high-fat diet group (HFDF), high fat diet with metformin administration group (METT), and high fat diet with MIT administration group (MITT). Each 10 mice were allocated to each group (a total of 40 mice). All mice were allowed to eat fat-rich diet freely throughout the experiment. To examine the effect of MIT, we observed Cannabinoid receptor type 1 (CB1), Cannabinoid receptor type 2 (CB2), G protein-coupled receptor 55 (GPR55), and Transforming growth factor-β (TGF-β). Results In the MITT group, positive reactions of the CB1, CB2, and GPR55 were significantly was significantly suppressed compared to the HFDF group. The positive reactions of the CD36 and TGF-β in the liver tissue were significantly suppressed in MITT. Conclusions MIT has the effect of improving NAFLD induced insulin resistance through the regulation of the lipid metabolism.

Keywords

References

  1. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11-20. https://doi.org/10.1038/nrgastro.2017.109
  2. Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol. 2013;10(11):656-665. https://doi.org/10.1038/nrgastro.2013.183
  3. Akshintala D, Chugh R, Amer F, Cusi K. Nonalcoholic Fatty Liver Disease: The Overlooked Complication of Type 2 Diabetes. [Updated 2019 Jul 9]. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK544043/
  4. Li L, Liu DW, Yan HY, Wang ZY, Zhao SH, Wang B. Obesity is an independent risk factor for non-alcoholic fatty liver disease: evidence from a meta-analysis of 21 cohort studies. Obes Rev. 2016;17(6):510-519. https://doi.org/10.1111/obr.12407
  5. E.L. Anderson, L.D. Howe, H.E. Jones, J.P. Higgins, D.A. Lawlor, A. Fraser. The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis. PLOS ONE, 2015;10:p.e0140908 https://doi.org/10.1371/journal.pone.0140908
  6. Lee BW. Management of patients with Nonalcoholic Fatty Liver Disease with lifestyle modification. Korean Diabetes. 2018;19(2):82-7. https://doi.org/10.4093/jkd.2018.19.2.82
  7. Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908-922. https://doi.org/10.1038/s41591-018-0104-9
  8. Pennisi G, Celsa C, Spatola F, Dallio M, Federico A, Petta S. Pharmacological therapy of Non-Alcoholic Fatty Liver Disease: what drugs are available now and future perspectives. Int J Environ Res Public Health. 2019;16(22):4334. https://doi.org/10.3390/ijerph16224334
  9. Bouillet B, Petit J, Sberna A, R Lofftoy, A Nguyen, L Duvillard, D Denimal, P Hillon, B Verges. Application of the new EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease (NAFLD) in people with type 2 diabetes. Diabetologia. 2017;60:S573-S574.
  10. Liu ZL, Xie LZ, Zhu J, Li GQ, Grant SJ, Liu JP. Herbal medicines for fatty liver diseases. Cochrane Database Syst Rev. 2013(8):CD009059.
  11. Yao H, Qiao YJ, Zhao YL, Tao XF, Xu LN, Yin LH, Qu Y, Peng JY. Herbal medicines and nonalcoholic fatty liver disease. World J Gastroenterol. 2016;22(30):6890-6905. https://doi.org/10.3748/wjg.v22.i30.6890
  12. Kim K, Ko H, Shin S. Diagnostic Process Analysis of Prescribing Injinho-tang in Non Alcohoic Fatty Liver Disease Using by AHP. The Journal of the Society of Korean Medicine Diagnostics. 2015;19(3):159-71.
  13. Jang YS, Seo JY, kwun MJ, Kwon JN, Lee I, Hong JW, Kim SY, Choi JY, Park SH, Joo M, Han CW. Effect of Phaseolus angularis Seed on Experimental Cellular Model of Nonalcoholic Fatty Liver Disease. Korean J. Oriental Physiology & Pathology. 2013;27(6):802-8.
  14. Kim SY, Kwon JN, Lee I, Hong JW, Choi JY, Park SH, Kwon MJ, Joo M, Han CW. Research on Anti-lipogenic Effect and Underlying Mechanism of Laminaria japonica on Experimental Cellular Model of Non-alcoholic Fatty Liver Disease. J. Int. Korean Med. 2014;35(2):175-83.
  15. Jung YS, Kim JH, Kim BC, Seok HJ, Yoo JS, Ku JR, Yoon KH, Jo JH, Jang DH, Yun HY, Yoon M, Shin SS. Comparison of Gangjihwan-1,2,3,4 and Combination of Gangjihwan-1 and Gamisochehwan in the Improvement Effects of Nonalcoholic Fatty Liver Disease in a High Fat Diet-Fed Obese Mouse Model. Kor. J. Herbology. 2014;29(6):149-56. https://doi.org/10.6116/kjh.2014.29.6.149.
  16. Han CW, Lee JH. Effects of KHchunggan-tang on the Nonalcoholic Fatty Liver Disease in Palmitate-induced Cellular Model. J Korean Oriental Med. 2011;32(1):109-20.
  17. Akbar DH, Kawther AH. Nonalcoholic fatty liver disease in Saudi type 2 diabetic subjects attending a medical outpatient clinic: prevalence and general characteristics. Diabetes Care. 2003;26(12):3351-2. https://doi.org/10.2337/diacare.26.12.3351-a
  18. Choi E, Jang E, Lee JH. Pharmacological activities of alisma orientale against Nonalcoholic Fatty Liver Disease and metabolic syndrome: literature review. Evid Based Complement Alternat Med. 2019;2019:2943162.
  19. Hong M, Lee YH, Kim S, Suk KT, Bang CS, Yoon JH, Baik GH, Kim DJ, Kim MJ. Anti-inflammatory and antifatigue effect of Korean Red Ginseng in patients with nonalcoholic fatty liver disease. J Ginseng Res. 2016;40(3):203-210. https://doi.org/10.1016/j.jgr.2015.07.006
  20. Fan Y, Li J, Yin Q, Zhang YS Y, Xu HF, Shi XH, Li C, Zhou Y, Zhou CX. Effect of extractions from Ephedra sinica Stapf on hyperlipidemia in mice. Exp Ther Med. 2015;9(2):619-625. https://doi.org/10.3892/etm.2014.2117
  21. Li Z, Kim HJ, Park MS, Ji GE. Effects of fermented ginseng root and ginseng berry on obesity and lipid metabolism in mice fed a high-fat diet. J Ginseng Res. 2018;42(3):312-319. https://doi.org/10.1016/j.jgr.2017.04.001
  22. Park TY, Hong M, Sung H, Kim S, Suk KT. Effect of Korean Red Ginseng in chronic liver disease. J Ginseng Res. 2017;41(4):450-455. https://doi.org/10.1016/j.jgr.2016.11.004
  23. Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med. 2012;52(1):59-69. https://doi.org/10.1016/j.freeradbiomed.2011.10.003
  24. Masarone M, Rosato V, Dallio M, Gravina AG, Aglitti A, Loguercio C, Federico A, Persico M. Role of oxidative stress in pathophysiology of Nonalcoholic Fatty Liver Disease. Oxid Med Cell Longev. 2018;2018:9547613. https://doi.org/10.1155/2018/9547613
  25. Son CG. A juvenile case with nonalcoholic steatohepatitis and traditional Korean medicine-based treatment. Integr Med Res. 2018;7(2):206-9. https://doi.org/10.1016/j.imr.2018.01.006
  26. Lawan A, Bennett AM. Mitogen-activated protein kinase regulation in hepatic metabolism. Trends Endocrin Met. 2017;28(12):868-878. https://doi.org/10.1016/j.tem.2017.10.007
  27. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44(4):865-73. https://doi.org/10.1002/hep.21327
  28. Fassio E, Alvarez E, Dominguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology. 2004;40(4):820-6. https://doi.org/10.1002/hep.1840400411
  29. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129(1):113-24. https://doi.org/10.1053/j.gastro.2005.04.014
  30. Jang IS, Yang CS, Hwang EH. The need for clinical practice guidelines in usage of Mahuang in weight loss. J Soc Kor Med Obesity Res. 2007;7(1):23-9
  31. Shon MS, Kim GN. Anti-obese Function of Polysaccharides derived from Korean Ginseng (Panax ginseng C.A. Meyer) and Development of Functional Food Material in Preventing Obesity. Kor. J. Herbol. 2016;31(4):1-77 https://doi.org/10.6116/kjh.2016.31.4.1.
  32. Kim EY, Lee JH. The effect of Alisma orientale extract on Free Fatty Acid-induced lipoapoptosis in HepG2 Cells. J. Int. Korean Med. 2014:35(2);184-194
  33. Choi J, Kim TH, Choi TY, Lee MS. Ginseng for health care: a systematic review of randomized controlled trials in Korean literature. PLoS One. 2013;8(4):e59978. https://doi.org/10.1371/journal.pone.0059978
  34. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34(3):274-285. https://doi.org/10.1111/j.1365-2036.2011.04724.x
  35. Zhong F, Zhou X, Xu J, Gao L. Rodent models of Nonalcoholic Fatty Liver Disease. Digestion. 2020;101(5):522-35 https://doi.org/10.1159/000501851
  36. Castro RE, Diehl AM. Towards a definite mouse model of NAFLD. J Hepatol. 2018;69(2):272-274. https://doi.org/10.1016/j.jhep.2018.05.002
  37. M. Salzet, Invertebrate molecular neuroimmune processes. Brain Res Rev. 2000;34(1-2):69-79. https://doi.org/10.1016/S0165-0173(00)00041-2
  38. H Yang, J Zhou, C Lehmann. GPR55 - a putative "type 3" cannabinoid receptor in inflammation J Basic Clin Physiol Pharmacol. 2016;27(3):297-302. https://doi.org/10.1515/jbcpp-2015-0080
  39. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Batkai S, Harbey-White J, Mackie K, Offertáler L, Wang L, Kunos G. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest. 2005;115(5):1298-305. https://doi.org/10.1172/JCI200523057
  40. T. Haruna, M. Soga, Y. Morioka, K Imura, Y Furue, M Yamamoto, J Hayakawa, M Deguchi, A Arimura, K Yasui. The Inhibitory effect of S-777469, a Cannabinoid Type 2 Receptor Agonist, on skin inflammation in mice. Pharmacology. 2017;99(5-6):259-267. https://doi.org/10.1159/000455916
  41. G. Cantarella, M. Scollo, L. Lempereur, G Saccani-Jotti, F Basile, E Bernardini. Endocannabinoids inhibit release of nerve growth factor by inflammation-activated mast cells. Biochem Pharmacol. 2011;82(4):380-8. https://doi.org/10.1016/j.bcp.2011.05.004
  42. Ahn SH, Yang ES, Cho HR, Lee SO, Ha KT, Kim KB. Herbal formulation MIT ameliorates high-fat diet-induced non-alcoholic fatty liver disease. Integrative Medicine Research. 2020;9(4):100422. https://doi.org/10.1016/j.imr.2020.100422
  43. Bhatia V, Viswanathan P. Insulin resistance and PPAR insulin sensitizers. Curr Opin Investig Drugs. 2006;7(10):891-7.
  44. Camella G. Wilson, Jennifer L. Tran, Derek M. Erion, Nicholas B. Vera, Maria Febbraio, Ethan J. Weiss. Hepatocyte-specific disruption of CD36 attenuates Fatty Liver and improves insulin sensitivity in HFDFed Mice. Endocrinology. 2016;157(2):570-85. https://doi.org/10.1210/en.2015-1866
  45. Harp JB. New insights into inhibitors of adipogenesis. A Curr Opin Lipidol. 2004;15(3):303-7. https://doi.org/10.1097/00041433-200406000-00010
  46. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 2003;113(6):685-700. https://doi.org/10.1016/S0092-8674(03)00432-X
  47. Wharton K, Derynck R. TGF-β family signaling: novel insights in development and disease, Development. 2009;136:3691-7. https://doi.org/10.1242/dev.040584
  48. Hong SH, Kang MY, Lee KS, Yu K. High fat diet-induced TGF-β/Gbb signaling provokes insulin resistance through the tribbles expression. Scientific reports. 2016:6:30265. https://doi.org/10.1038/srep30265